Dynamic Technology Lab Private Ltd grew its holdings in Shire PLC (NASDAQ:SHPG) by 131.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,689 shares of the biopharmaceutical company’s stock after buying an additional 3,234 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Shire PLC were worth $871,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of SHPG. Janus Henderson Group PLC increased its position in shares of Shire PLC by 22,560.3% in the second quarter. Janus Henderson Group PLC now owns 1,286,881 shares of the biopharmaceutical company’s stock valued at $212,683,000 after buying an additional 1,281,202 shares in the last quarter. Glenview Capital Management LLC increased its position in shares of Shire PLC by 69.7% in the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after buying an additional 707,500 shares in the last quarter. Northern Trust Corp increased its position in shares of Shire PLC by 45.5% in the second quarter. Northern Trust Corp now owns 1,307,339 shares of the biopharmaceutical company’s stock valued at $216,064,000 after buying an additional 408,843 shares in the last quarter. OZ Management LP purchased a new stake in shares of Shire PLC in the second quarter valued at approximately $57,614,000. Finally, Maverick Capital Ltd. increased its position in shares of Shire PLC by 19.9% in the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after buying an additional 322,610 shares in the last quarter. Institutional investors and hedge funds own 18.64% of the company’s stock.

Shire PLC (NASDAQ:SHPG) opened at $149.78 on Thursday. The firm has a market capitalization of $43,510.84, a price-to-earnings ratio of 9.96, a price-to-earnings-growth ratio of 0.80 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. Shire PLC has a 12 month low of $137.17 and a 12 month high of $192.15.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. The company had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period last year, the firm posted $3.17 EPS. equities analysts forecast that Shire PLC will post 15 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/23/shire-plc-shpg-stake-increased-by-dynamic-technology-lab-private-ltd.html.

A number of research firms have recently commented on SHPG. Cantor Fitzgerald restated a “buy” rating and issued a $222.00 price objective on shares of Shire PLC in a research report on Thursday, September 14th. Royal Bank Of Canada restated a “buy” rating on shares of Shire PLC in a research report on Thursday, November 16th. Barclays PLC cut Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Jefferies Group LLC restated a “hold” rating and issued a $206.00 price objective (down from $216.00) on shares of Shire PLC in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $212.18.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.